Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.2 Rising prevalence of diabetes
3.2.3 Increasing research & development activities
3.2.4 Growing demand for non-injectable emergency glycogen
3.2.5 Advancements in pharmaceutical sector
3.2.6 Industry pitfalls & challenges
3.2.7 Lack of consumer awareness
3.2.8 Stringent regulatory framework
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Company matrix analysis
4.5 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Injectable
5.3 Inhalation
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Hypoglycemia
6.3 Diagnostic aid
6.4 Gastrointestinal disorders
6.5 Cardiogenic shock
6.6 Other applications
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Amgen Inc.
9.2 Avalon Pharma Private Limited
9.3 Bachem Holding AG
9.4 Eli Lilly and Company
9.5 Fresenius SE & Co. KGaA
9.6 Fujifilm Holdings Corporation
9.7 Novo Nordisk A/S
9.8 Pfizer, Inc.
9.9 Svar Life Science
9.10 Taj Pharmaceuticals Ltd.
9.11 Xeris Biopharma Holdings, Inc.
